Prof. Ruth Ladenstein, executive director of the Medicines for Children Research Organisation (OKIDS) in Austria, explains OKIDS’ drive to ensure drugs are paediatric specific by conducting child-specific clinical trials. Furthermore, she highlights the challenges associated with achieving a participating child’s consent and defines what must be done to gain governmental and industry support to bolster this sector in the future.
Can you explain the role of OKIDS and the main challenges that you face today?
"We were created because children have become isolated from the field of industry-driven clinical trials."
